UY28149A1 - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
UY28149A1
UY28149A1 UY28149A UY28149A UY28149A1 UY 28149 A1 UY28149 A1 UY 28149A1 UY 28149 A UY28149 A UY 28149A UY 28149 A UY28149 A UY 28149A UY 28149 A1 UY28149 A1 UY 28149A1
Authority
UY
Uruguay
Prior art keywords
chemical compounds
therapy
compositions
contain
processes
Prior art date
Application number
UY28149A
Other languages
English (en)
Inventor
Nicola Murdoch Heron
Andrew Austen Mortlock
Fredrick Henri Jung
Georges Rene Pasquet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28149A1 publication Critical patent/UY28149A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de quinazolina de fórmula (I): donde A es un heteroarilo de 5 miembros que contiene un átomo de nitrógeno y uno o dos átomos de nitrógeno adicionales; composiciones que los contienen, procesos para su preparación y su uso en terapia.
UY28149A 2002-12-24 2003-12-23 Compuestos quimicos UY28149A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (1)

Publication Number Publication Date
UY28149A1 true UY28149A1 (es) 2004-07-30

Family

ID=32683824

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28149A UY28149A1 (es) 2002-12-24 2003-12-23 Compuestos quimicos

Country Status (30)

Country Link
US (4) US7528121B2 (es)
EP (2) EP1578755B1 (es)
JP (3) JP4422102B2 (es)
KR (1) KR101010299B1 (es)
AR (2) AR042668A1 (es)
AT (2) ATE438644T1 (es)
AU (1) AU2003290313B2 (es)
BR (1) BRPI0317717B8 (es)
CA (1) CA2511613C (es)
CL (1) CL2003002731A1 (es)
CY (2) CY1107775T1 (es)
DE (2) DE60315892T2 (es)
DK (2) DK1847539T3 (es)
ES (2) ES2329623T3 (es)
HK (2) HK1080481A1 (es)
IL (2) IL169112A (es)
IS (2) IS2504B (es)
MX (1) MXPA05006918A (es)
MY (2) MY147761A (es)
NO (2) NO335193B1 (es)
NZ (1) NZ540698A (es)
PL (2) PL221490B1 (es)
PT (2) PT1578755E (es)
RU (3) RU2350611C1 (es)
SA (1) SA04240504B1 (es)
SI (2) SI1847539T1 (es)
TW (2) TWI393710B (es)
UA (1) UA83814C2 (es)
UY (1) UY28149A1 (es)
WO (1) WO2004058781A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101029281B1 (ko) * 2001-12-24 2011-04-18 아스트라제네카 아베 오로라 키나제의 억제제로서 치환된 퀴나졸린 유도체
EP1578755B1 (en) * 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
JP2006516138A (ja) * 2002-12-24 2006-06-22 アストラゼネカ アクチボラグ キナゾリン化合物
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer
EP2251343A1 (en) * 2003-05-15 2010-11-17 Arqule, Inc. Imidazothiazoles as p38-kinase-inhibitors
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
EP1802591B1 (en) * 2004-10-12 2012-01-11 AstraZeneca AB Quinazoline derivatives
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
US20110136766A1 (en) * 2008-03-04 2011-06-09 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
US8138194B2 (en) 2008-04-30 2012-03-20 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
JP2011526912A (ja) * 2008-07-03 2011-10-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのナフチリジノン
AU2009322158A1 (en) * 2008-12-05 2010-06-10 Arqule, Inc. RAF inhibitors and their uses
CN104860913B (zh) 2008-12-11 2018-05-04 艾克赛特药品有限公司 染料木黄酮的晶型
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
CN102264368B (zh) 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
EP2958895B1 (en) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP6301374B2 (ja) * 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
AP2016009088A0 (en) * 2013-09-16 2016-03-31 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
CN106061261B (zh) 2013-11-01 2018-04-24 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
CN109688818A (zh) 2016-09-08 2019-04-26 卡拉制药公司 治疗化合物的晶型及其用途
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20200066292A (ko) 2017-09-08 2020-06-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Enpp1 억제제 및 암의 치료를 위한 그의 용도
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
AU716330B2 (en) 1995-12-18 2000-02-24 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
DK0880508T3 (da) 1996-02-13 2003-06-30 Astrazeneca Ab Quinazolinderivater som VEGF-inhibitorer
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
EP1119567B1 (en) * 1998-10-08 2005-05-04 AstraZeneca AB Quinazoline derivatives
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CA2384291A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
US6919338B2 (en) 2000-06-28 2005-07-19 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1408980A4 (en) * 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
KR101029281B1 (ko) * 2001-12-24 2011-04-18 아스트라제네카 아베 오로라 키나제의 억제제로서 치환된 퀴나졸린 유도체
JP2006516138A (ja) * 2002-12-24 2006-06-22 アストラゼネカ アクチボラグ キナゾリン化合物
EP1578755B1 (en) * 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer

Also Published As

Publication number Publication date
CA2511613A1 (en) 2004-07-15
AU2003290313A1 (en) 2004-07-22
US8268841B2 (en) 2012-09-18
IL169112A0 (en) 2009-02-11
ES2290529T3 (es) 2008-02-16
IS7948A (is) 2005-07-20
US9018191B2 (en) 2015-04-28
NO20052855L (no) 2005-08-03
SI1847539T1 (sl) 2010-01-29
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
BRPI0317717B1 (pt) 2017-12-19
CL2003002731A1 (es) 2005-01-07
PL412704A1 (pl) 2015-10-12
US20060116357A1 (en) 2006-06-01
DE60315892T2 (de) 2008-08-14
NO335446B1 (no) 2014-12-15
JP4422102B2 (ja) 2010-02-24
HK1080481A1 (en) 2006-04-28
DE60328735D1 (de) 2009-09-17
JP4503090B2 (ja) 2010-07-14
US20140162984A1 (en) 2014-06-12
MY147761A (en) 2013-01-31
TWI393710B (zh) 2013-04-21
IS2504B (is) 2009-04-15
PL223998B1 (pl) 2016-11-30
DK1578755T3 (da) 2007-11-12
ATE370958T1 (de) 2007-09-15
PL377680A1 (pl) 2006-02-06
US20150307534A1 (en) 2015-10-29
ATE438644T1 (de) 2009-08-15
BR0317717A (pt) 2005-11-22
US9567358B2 (en) 2017-02-14
IS8714A (is) 2008-02-13
EP1578755A1 (en) 2005-09-28
AU2003290313B2 (en) 2007-05-10
JP2009046514A (ja) 2009-03-05
KR101010299B1 (ko) 2011-01-25
CA2511613C (en) 2012-10-02
CY1109479T1 (el) 2014-08-13
NZ540698A (en) 2008-05-30
JP4906608B2 (ja) 2012-03-28
IL185176A (en) 2011-10-31
JP2006512418A (ja) 2006-04-13
EP1847539B1 (en) 2009-08-05
IL169112A (en) 2010-12-30
RU2007121850A (ru) 2008-12-20
MXPA05006918A (es) 2005-08-18
US20100069412A1 (en) 2010-03-18
TW201102369A (en) 2011-01-16
NO20052855D0 (no) 2005-06-13
TWI336327B (en) 2011-01-21
IS2884B (is) 2014-06-15
BRPI0317717B8 (pt) 2021-05-25
EP1847539A1 (en) 2007-10-24
WO2004058781A1 (en) 2004-07-15
SA04240504B1 (ar) 2008-04-01
SA04240504A (ar) 2005-12-03
DK1847539T3 (da) 2009-11-09
CY1107775T1 (el) 2013-06-19
RU2005123485A (ru) 2006-03-10
PL221490B1 (pl) 2016-04-29
TW200510342A (en) 2005-03-16
DE60315892D1 (de) 2007-10-04
NO335193B1 (no) 2014-10-20
US7528121B2 (en) 2009-05-05
JP2007326862A (ja) 2007-12-20
NO20131444L (no) 2005-08-03
UA83814C2 (ru) 2008-08-26
PT1847539E (pt) 2009-10-06
RU2350611C1 (ru) 2009-03-27
SI1578755T1 (sl) 2007-12-31
IL185176A0 (en) 2007-12-03
HK1111417A1 (en) 2008-08-08
PT1578755E (pt) 2007-10-19
EP1578755B1 (en) 2007-08-22
MY136174A (en) 2008-08-29
ES2329623T3 (es) 2009-11-27
KR20050088333A (ko) 2005-09-05
RU2357971C2 (ru) 2009-06-10

Similar Documents

Publication Publication Date Title
UY28149A1 (es) Compuestos quimicos
MXPA05006920A (es) Compuestos de quinazolina.
UY27604A1 (es) Compuestos químicos.
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
BR0111667A (pt) Novos compostos
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
NO20044995L (no) Heterosykliske forbindelser
NO20013379L (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
BR0211427A (pt) Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos
AU2003294142A1 (en) Therapeutic quinazoline derivatives
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DE60121461D1 (de) Kondensierte pyridoindolderivate
BR0209936A (pt) Composição combinada farmacêutica,e uso de um composto e de um inibidor de cianoguanidina ikk
BRPI0407841A (pt) inibidores heterocìclicos de quinase
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
BR0111669A (pt) Novos compostos
UY28685A1 (es) Heterociclos con contenido de nitrógeno que afectan la transmisión sináptica glutamatérgica
DE60110124D1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
ATE274515T1 (de) Pyrazolopyridinderivate
BR0211180A (pt) Compostos, processo para preparar os mesmos, intermediários, e, composição adequada e método para controlar fungos fitopatogênicos
UA86470C2 (ru) Производные фосфонооксихиназолина и их фармацевтическое применение
DE60219788D1 (de) Tetrazyklische verbindungen als pde5-inhibitoren
WO2002087587A3 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20160919